10x Genomics, Inc. TXG
Set alert
70.11 USD -11.44 -14.03%
At close · Oct 30
69.80 -0.31 -0.44%
After hours · Oct 30, 7:23 PM ET
67.42 Day range 75.77
12.44 52-week range 97.74
- YTD
- +329.86%
- 1 year
- +463.59%
- Open
- 73.65
- Prev close
- 81.55
- Mkt cap
- 9.13B
- Vol
- 5.22M
- Avg vol
- 3.37M
- EPS
- -0.59
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 67.42
- High
- 75.77
- Forward P/E
- 913.53
- Beta
- 1.99
- Short ratio
- 3.09
- Inst. own
- 116.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 74.05
- 200-d avg
- 40.33
- 1y target
- 77.50
MAX chart
Events in this range
- Aug 7, 2025Earnings: 0.28; estimate -0.35; surprise 180%
- Nov 6, 2025Earnings: -0.22; estimate -0.07; surprise -214.29%
- Feb 12, 2026Earnings: -0.13; estimate -0.19; surprise 31.58%
- May 7, 2026Earnings: -0.1; estimate -0.29; surprise 65.52%
- Aug 6, 2026Earnings: -0.14; estimate -0.24308; surprise 42.41%
- Sep 28, 2026Rating: Piper Sandler · Neutral → Neutral
- Sep 29, 2026Rating: Leerink Partners · Market Perform → Market Perform
- Oct 7, 2026Rating: Barclays · Overweight → Overweight
- Oct 12, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 13, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Oct 13, 2026Rating: TD Cowen · Hold → Hold
- Nov 5, 2026Earnings: —; estimate -0.267; surprise —%
Signals (128)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 1 day ago |
| MACD: Sell Signal | Oct 30, 2026 | 1 day ago |
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| RSI: Overbought | Jun 15, 2026 | 4 months ago |
| RSI: Overbought | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 25, 2026 | 5 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Feb 16, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| RSI: Overbought | Jan 19, 2026 | 9 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| MACD: Buy Signal | May 5, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 10, 2025 | 1 year ago |
| RSI: Oversold | Mar 10, 2025 | 1 year ago |
| RSI: Oversold | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Dec 2, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 25, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 11, 2024 | 1 year ago |
| RSI: Oversold | Nov 11, 2024 | 1 year ago |
| RSI: Oversold | Oct 14, 2024 | 2 years ago |
| SMA: Bearish | Sep 30, 2024 | 2 years ago |
| SMA: Bullish | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| RSI: Oversold | May 6, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 26, 2024 | 2 years ago |
| SMA: Bearish | Feb 19, 2024 | 2 years ago |
| SMA: Bearish | Feb 12, 2024 | 2 years ago |
| SMA: Bullish | Feb 5, 2024 | 2 years ago |
| SMA: Bullish | Feb 5, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 5, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 8, 2024 | 2 years ago |
| SMA: Bearish | Jan 8, 2024 | 2 years ago |
| SMA: Bullish | Dec 4, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 27, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| SMA: Bullish | Aug 28, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 17, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 3, 2023 | 3 years ago |
| SMA: Bullish | May 29, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| SMA: Bullish | Mar 13, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Dec 26, 2022 | 3 years ago |
| SMA: Bearish | Dec 5, 2022 | 3 years ago |
| SMA: Bullish | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| SMA: Bullish | Oct 31, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| SMA: Bearish | Jun 27, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| RSI: Oversold | May 30, 2022 | 4 years ago |
| MACD: Buy Signal | May 23, 2022 | 4 years ago |
| RSI: Oversold | Apr 18, 2022 | 4 years ago |
| SMA: Bearish | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 28, 2022 | 4 years ago |
| RSI: Oversold | Feb 14, 2022 | 4 years ago |
| RSI: Oversold | Jan 17, 2022 | 4 years ago |
| SMA: Bearish | Nov 15, 2021 | 4 years ago |
| SMA: Bearish | Nov 8, 2021 | 4 years ago |
| SMA: Bullish | Nov 1, 2021 | 5 years ago |
| SMA: Bullish | Nov 1, 2021 | 5 years ago |
| SMA: Bearish | Oct 25, 2021 | 5 years ago |
| SMA: Bullish | Oct 18, 2021 | 5 years ago |
| SMA: Bearish | Sep 13, 2021 | 5 years ago |
| SMA: Bearish | Sep 13, 2021 | 5 years ago |
| SMA: Bullish | Aug 30, 2021 | 5 years ago |
| SMA: Bullish | Aug 30, 2021 | 5 years ago |
| SMA: Bearish | Aug 2, 2021 | 5 years ago |
| SMA: Bearish | Jul 26, 2021 | 5 years ago |
| SMA: Bullish | Jul 19, 2021 | 5 years ago |
| SMA: Bullish | Jul 19, 2021 | 5 years ago |
| SMA: Bearish | Jul 12, 2021 | 5 years ago |
| SMA: Bearish | Jul 12, 2021 | 5 years ago |
| SMA: Bullish | May 24, 2021 | 5 years ago |
| SMA: Bullish | May 24, 2021 | 5 years ago |
| SMA: Bearish | May 3, 2021 | 5 years ago |
| SMA: Bearish | May 3, 2021 | 5 years ago |
| MACD: Sell Signal | May 3, 2021 | 5 years ago |
| MACD: Buy Signal | Apr 26, 2021 | 5 years ago |
| SMA: Bullish | Mar 29, 2021 | 5 years ago |
| SMA: Bearish | Mar 1, 2021 | 5 years ago |
| MACD: Sell Signal | Mar 1, 2021 | 5 years ago |
| RSI: Overbought | Feb 8, 2021 | 5 years ago |
| MACD: Buy Signal | Jan 11, 2021 | 5 years ago |
| RSI: Overbought | Jan 11, 2021 | 5 years ago |
| SMA: Bullish | Jan 4, 2021 | 5 years ago |
| SMA: Bearish | Dec 28, 2020 | 5 years ago |
| MACD: Sell Signal | Dec 7, 2020 | 5 years ago |
| SMA: Bullish | Nov 23, 2020 | 5 years ago |
| SMA: Bearish | Nov 16, 2020 | 5 years ago |
| RSI: Overbought | Sep 7, 2020 | 6 years ago |
| RSI: Overbought | Aug 17, 2020 | 6 years ago |
| MACD: Buy Signal | Jun 15, 2020 | 6 years ago |
| SMA: Bullish | Apr 13, 2020 | 6 years ago |
| SMA: Bullish | Apr 13, 2020 | 6 years ago |
| SMA: Bearish | Feb 17, 2020 | 6 years ago |
| RSI: Overbought | Jan 13, 2020 | 6 years ago |
Key statistics
- Market cap
- 9.13B
- Enterprise value
- 10.15B
- Trailing P/E
- 0.00
- Forward P/E
- 913.53
- PEG ratio
- 0.00
- Price / sales
- 14.79
- Price / book
- 11.05
- EPS (TTM)
- -0.59
- Beta
- 1.99
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -12.18%
- Revenue (TTM)
- 616.91M
- Revenue growth
- -12.70%
- Free cash flow
- 179.66M
- Total cash
- 552.03M
- Total debt
- 78.80M
- Return on equity
- -9.40%
- Shares outstanding
- 120.21M
- Short % of float
- 14.33%
- 50-day average
- 74.05
- 200-day average
- 40.33
Analyst view
Consensus: buy
Buy
Price target (mean) 77.50 +10.5% upside
Now 70.11
- Target (low)
- 50.00
- Target (mean)
- 77.50
- Target (high)
- 110.00
Ratings (0m) 18 6 buy · 12 hold · 0 sell
- Strong buy1
- Buy5
- Hold12
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.02.
Financials — quick view
TXG Revenue — quarterly 151.04M
TXG Net income — quarterly -17.93M
TXG EPS — quarterly -0.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.267 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.24308 | -0.14 | +0.10 | +42.41% |
| May 7, 2026 | Mar 31, 2026 | -0.29 | -0.10 | +0.19 | +65.52% |
| Feb 12, 2026 | Dec 31, 2025 | -0.19 | -0.13 | +0.06 | +31.58% |
| Nov 6, 2025 | Sep 30, 2025 | -0.07 | -0.22 | -0.15 | -214.29% |
| Aug 7, 2025 | Jun 30, 2025 | -0.35 | 0.28 | +0.63 | +180.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | main | Hold | Hold |
| Oct 13, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 12, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Sep 29, 2026 | Leerink Partners | main | Market Perform | Market Perform |
| Sep 28, 2026 | Piper Sandler | main | Neutral | Neutral |
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- 10xgenomics.com
News
- 3 Promising Genomics Stocks to Add to Your Portfolio Now
- Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday
- 10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
- A Look at 10x Genomics Inc (TXG) After 3.5% Decline -- GF Value $18.31 vs Price $69.86
- 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
- TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70
- Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70
- Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100
- These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
Your note
Sign in to keep a note on TXG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HINDSON BENJAMIN J | President | Sale | Aug 23, 2026 | 488,182 |
| KOSARAJU SRIDHAR | Director | Stock Award(Grant) | Jun 3, 2026 | 68,278 |
| MATEO ALAN V. | Director | Stock Award(Grant) | Jun 3, 2026 | 85,877 |
| POPOVITS KIMBERLY J | Director | Stock Award(Grant) | Jun 3, 2026 | 37,445 |
| SAXONOV SERGE WILSON | Chief Executive Officer | Sale | Sep 21, 2026 | 1,335,170 |
| STUELPNAGEL JOHN R | Director | Sale | Sep 2, 2026 | 328,436 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.67% | 17,629,266 | 1.23B | Jun 29, 2026 |
| Blackrock Inc. | 8.99% | 10,804,070 | 756.72M | Jun 29, 2026 |
| ARK Investment Management, LLC | 8.32% | 10,003,057 | 700.61M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.81% | 6,982,492 | 489.05M | Jun 29, 2026 |
| Quantinno Capital Management, LP | 4.55% | 5,469,698 | 383.10M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.23% | 5,082,594 | 355.98M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.94% | 3,528,683 | 247.15M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.62% | 3,148,101 | 220.49M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.52% | 3,032,629 | 212.41M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.12% | 2,548,523 | 178.50M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.08% | 2,498,429 | 174.99M | Sep 29, 2026 |
| Fidelity Select PORT.s-Select Medical Technology and Devices PORT. | 1.99% | 2,392,772 | 167.59M | Aug 30, 2026 |